Genentech, Biogen Settle Patent Infringement Suit Over Actemra

Genentech Inc. has reached a settlement with Biogen MA Inc. over allegations that a drug that Biogen planned to release infringed 20 patents relating to a Genentech drug sold to treat rheumatoid arthritis.

Genentech had alleged that Biogen had been uncooperative in following the streamlined process under the Biologics Price Competition and Innovation Act to ensure that the biosimilar BIIB800 didn’t infringe patents relating to Actemra. A joint stipulation of dismissal was filed Monday in the US District Court for the District of Massachusetts.

• After entering into a settlement agreement, the parties agreed to voluntarily dismiss all claims ...